Long-Term Follow-Up of Patients in Four Prospective Studies of the German Breast Cancer Study Group (GBSG): A Summary of Key Results

2002 ◽  
Vol 25 (2) ◽  
pp. 143-150 ◽  
Author(s):  
C. Schmoor ◽  
M. Olschewski ◽  
W. Sauerbrei ◽  
M. Schumacher
Keyword(s):  
Breast Cancer ◽  
Prospective Studies ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study ◽  
Long Term Follow Up

scholarly journals Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

2016 ◽  
Vol 34 (9) ◽  
pp. 927-935 ◽  
Author(s):  
Marco Colleoni ◽  
Zhuoxin Sun ◽  
Karen N. Price ◽  
Per Karlsson ◽  
John F. Forbes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Strategies ◽  
Disease Free Survival ◽  
Entire Group ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study ◽  
Er Positive

Purpose Predicting the pattern of recurrence can aid in the development of targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer. Patients and Methods International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 and 1985. Annualized hazards were estimated for breast cancer–free interval (primary end point), disease-free survival, and overall survival. Results For the entire group, the annualized hazard of recurrence was highest during the first 5 years (10.4%), with a peak between years 1 and 2 (15.2%). During the first 5 years, patients with estrogen receptor (ER) – positive disease had a lower annualized hazard compared with those with ER-negative disease (9.9% v 11.5%; P = .01). However, beyond 5 years, patients with ER-positive disease had higher hazards (5 to 10 years: 5.4% v 3.3%; 10 to 15 years: 2.9% v 1.3%; 15 to 20 years: 2.8% v 1.2%; and 20 to 25 years: 1.3% v 1.4%; P < .001). Among patients with ER-positive disease, annualized hazards of recurrence remained elevated and fairly stable beyond 10 years, even for those with no axillary involvement (2.0%, 2.1%, and 1.1% for years 10 to 15, 15 to 20, and 20 to 25, respectively) and for those with one to three positive nodes (3.0%, 3.5%, and 1.5%, respectively). Conclusion Patients with ER-positive breast cancer maintain a significant recurrence rate during extended follow up. Strategies for follow up and treatments to prevent recurrences may be most efficiently applied and studied in patients with ER-positive disease followed for a long period of time.

Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI

2007 ◽  
Vol 43 (11) ◽  
pp. 1646-1653 ◽  
Author(s):  
Ann Partridge ◽  
Shari Gelber ◽  
Richard D. Gelber ◽  
Monica Castiglione-Gertsch ◽  
Aron Goldhirsch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Long Term Results ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study

scholarly journals The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up

1994 ◽  
Vol 5 (8) ◽  
pp. 717-724 ◽  
Author(s):  
M. Castiglione-Gertsch ◽  
C. Johnsen ◽  
A. Goldhirsch ◽  
R.D. Gelber ◽  
C.M. Rudenstam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study

Late Intensification Therapy in Adult Acute Lymphoid Leukemia: Long-Term Follow-Up of the Southeastern Cancer Study Group Experience

1994 ◽  
Vol 15 (1-2) ◽  
pp. 71-78 ◽  
Author(s):  
George A. Omura ◽  
W. Ralph Vogler ◽  
Orlando Martelo ◽  
David S. Gordon ◽  
Alfred A. Bartolucci
Keyword(s):  
Study Group ◽  
Lymphoid Leukemia ◽  
Cancer Study ◽  
Acute Lymphoid Leukemia ◽  
Cancer Study Group ◽  
Long Term Follow Up ◽  
Group Experience

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.

1994 ◽  
Vol 12 (10) ◽  
pp. 2086-2093 ◽  
Author(s):  
M Schumacher ◽  
G Bastert ◽  
H Bojar ◽  
K Hübner ◽  
M Olschewski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Treatment Modalities ◽  
Study Group ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study

PURPOSE In 1984, the German Breast Cancer Study Group (GBSG) started a multicenter randomized clinical trial to compare the effectiveness of three versus six cycles of 500 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, and 600 mg/m2 fluorouracil (CMF) on day 1 and 8 starting perioperatively with or without tamoxifen (TAM) (3 x 10 mg/d for 2 years). The aim of the trial was to compare recurrence-free and overall survival between the different treatment modalities. PATIENTS AND METHODS During 5 years, 41 institutions randomized 473 patients (3 x CMF: 145; 3 x CMF + TAM: 93; 6 x CMF 144; 6 x CMF + TAM: 91). Until March 31, 1992, median follow-up time was 56 months with 197 events for disease-free survival and 116 deaths observed. This provides a power of approximately 80% to detect a potential treatment difference corresponding to a relative risk (RR) of 0.67 for recurrence-free survival. Treatment modalities and various patient characteristics were evaluated by means of a multivariate Cox regression analysis. RESULTS No significant difference in recurrence-free survival was observed with respect to hormonal therapy (RR = 0.75 TAM v no TAM; 95% confidence interval [CI], 0.54 to 1.04; P = .08) as well as duration of chemotherapy (RR = 0.90 of 6 x CMF v 3 x CMF; 95% CI, 0.67 to 1.19; P = .45). Similar results were obtained for overall survival. The multivariate analysis revealed a significant prognostic impact of the number of positive lymph nodes and the progesterone receptor level on recurrence-free survival. Compliance with chemotherapy within the range of 85% to 115% of the target dose was achieved in 94% and 78% of the patients randomized to 3 x CMF and 6 x CMF, respectively. Sufficient compliance with TAM was reported for 141 patients (93%). CONCLUSION At this stage of follow-up, six courses of CMF are not superior to three courses with respect to recurrence-free survival.

Sign in / Sign up

Export Citation Format

Share Document